Premeeting Workshop:
PW11. Medication Assisted Treatment Waiver Course
Tuesday, October 2, 2018: 1:00 PM-5:30 PM
Room: W 2014-2016

  • At_Home_Induction_Patient_Pamphlet (2)[2].pdf (523.4 kB)
  • bupe 1 and 2.pdf (3.3 MB)
  • Other Care for patients with OUD.pdf (320.4 kB)
  • PHP Beehive Buprenorphine Treatment Guidelines.2013[2].pdf (312.3 kB)
  • QUICK+GUIDE-+Buprenorphine+-+04-18-18.pdf (480.8 kB)
  • MAT Slide Deck 1.pdf (1023.9 kB)
  • MAT Slide Deck 2.pdf (424.0 kB)
  • MAT Slide Deck 3.pdf (527.1 kB)
  • Learning Objectives:

    Upon completion of the first 4 hours of training in-person and the second 4 hours of training online, the participants will be able to:

    • have the training required to apply for a waiver to prescribe buprenorphone to their patients with opioid dependence (addiction)
    • identify and assess patients who are appropriate for treatment with buprenorphine
    • have the specific knowledge concerning the use of buprenorphine to manage opioid dependence in the outpatient setting
    • discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Target Audience: Clinicians, Healthcare workers, HIV clinicians, HIV specialists, Infection preventionists, Infectious diseases physicians

    Tracks: HIV-STD-TB, Adult ID

    Pre-Meeting Workshop Panelist:  Joshua Barocas, MD, Boston Medical Center

    Pre-Meeting Workshop Moderators:  Phillip Coffin, MD, MIA, San Francisco Department of Public Health and Hannah Snyder, MD, University of California San Francisco

    1:00 PM
    1:45 PM
    Patient Evaluation
    2:45 PM
    3:00 PM
    Case Study #1
    3:45 PM
    Use of Buprenorphine
    4:30 PM
    Case Study #2
    5:15 PM
    Completing the Notification Form and Wrap Up

    CME Credits: Maximum of 4.00 hours of AMA PRA Category 1 Credit™


    P. Coffin, None

    J. Barocas, None

    See more of: Premeeting Workshop

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.